Aim: The tuberculin skin test (TST) is used to diagnose tuberculosis; however, the influence of tumor necrosis factor (TNF) inhibitors on the test is unclear. This study investigated whether therapy with TNF inhibitors suppresses the TST reaction due to immunosuppression or whether the TST reaction increases due to reactivation of latent Mycobacterium tuberculosis infection.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory disease of the joints. 1 Tumor necrosis factor (TNF) inhibitors are more effective for preventing joint destruction than conventional disease-modifying anti-rheumatic drugs (DMARDs). 2 However, TNF inhibitors increase the risk of opportunistic infections, including reactivation of tuberculosis (TB), probably due to suppression of cell-mediated immunity. 3 The incidence of TB in Japan is 19 per 100 000 (0.019%), 4 which is relatively high among developed countries. Post-marketing surveillance has demonstrated that the incidence of new-onset TB in Japanese RA patients treated with infliximab or etanercept was 0.18% and 0.07%, respectively. 5, 6 Patients with latent TB infection (LTBI) are those who carry Mycobacterium tuberculosis without signs or symptoms of TB. When LTBI is diagnosed in patients with RA, the risk of developing TB can be reduced by starting prophylaxis with anti-TB drugs such as isoniazid before initiation of TNF inhibitors. 5 As more RA patients are being treated with TNF inhibitors, the number of patients at risk of developing TB is increasing. It has been established that the tuberculin skin test (TST) and interferon-c release assay (IGRA) are useful for LTBI screening before starting TNF inhibitors. 7 Several authors have recommended repeating the TST because an initial negative test becomes positive in some patients during therapy with TNF inhibitors, signifying either reactivation of TB or new infection. [8] [9] [10] [11] However, there have been few reports regarding the influence of TNF inhibitors on the results of the TST. 10, [12] [13] [14] In Japan, the majority of the population have a positive TST because bacillus Calm ette-Gu erin (BCG) vaccination is routinely provided. 15 This study was performed to examine whether long-term therapy with TNF inhibitors suppresses the TST reaction or whether the TST reaction increases due to activation of LTBI. Accordingly, we compared the TST reaction in RA patients between before therapy with TNF inhibitors and more than 1 year after starting them.
MATERIALS AND METHODS

Patients
This longitudinal study was performed to compare the TST reaction before and after initiation of therapy with TNF inhibitors. Of 209 adult RA patients attending the Division of Rheumatology and Clinical Immunology of Jichi Medical University Hospital between 2008 and 2009 who had been treated with infliximab or etanercept for longer than 1 year, 91 patients gave written informed consent to this study before inclusion. In all 91 patients, the TST was performed to screen for tuberculosis before starting TNF inhibitors. This study was approved by the Institutional Review Board of Jichi Medical University and was performed in compliance with the 1964 Declaration of Helsinki and subsequent versions. This study was also registered in the University Hospital Medical Information Network database (UMIN000021048).
Performance and assessment of the TST
We performed the TST before (T1) and more than 1 year after (T2) the start of therapy with TNF inhibitors. Purified protein derivative (PPD) of tuberculin (Japan BCG Laboratory, Tokyo, Japan) was utilized for TST according to the manufacturer's protocol. The reaction was evaluated by physicians from 48 to 72 h after intra-dermal injection of 0.1 mL of 0.5 lg/mL of PPD solution on the flexor side of the forearm and was classified as negative, weakly positive, moderately positive and strongly positive. A negative reaction was defined as no erythema or erythema with the major axis < 10 mm and no induration; weakly positive was defined as erythema with the major axis ≥ 10 mm and no induration; moderately positive was defined as erythema with the major axis ≥ 10 mm and induration; and strongly positive was defined as erythema with the major axis ≥ 10 mm and induration with double-redness (erythema in erythema), vesicles or necrosis. If the TST reaction was moderately or strongly positive at T1, the patient received prophylaxis with isoniazid (300 mg/ day) for a total of 9 months from at least 3 weeks before starting TNF inhibitors. Regardless of whether the reaction was positive or negative, patients who had a history of TB or contact with TB patients received isoniazid prophylaxis according to the same protocol.
Statistical analysis
Statistical analysis was performed using EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan), 16 which is a graphical user interface for R version 3.1.1 (The R Foundation for Statistical Computing, Vienna, Austria). EZR is a modified version of R commander version 2.1-2 with additional functions used in biostatistics. The TST reaction was compared between T1 and T2 by the Wilcoxon signed-rank test and calculation of Spearman's rank correlation coefficients. The dose of prednisolone was compared between T1 and T2 by the Wilcoxon signed-rank test. Statistical significance was defined as P < 0.05.
RESULTS
Patient profile
The characteristics of the 91 RA patients included in this study are summarized in Table 1 . There were 15 (16.5%) men and 76 (73.5%) women with a median age of 57 years (range: 17-85 years). Forty patients (44.0%) were treated with infliximab and 51 (56.0%) patients received etanercept. The median duration of the therapy was 2.4 years, with a range of 1.0-4.6 years. LTBI was diagnosed in 45 patients (49.5%) on the basis of the TST, IGRA, chest imaging findings and/or history of contact with patients having active TB. All of the patients with a diagnosis of LTBI received prophylaxis with isoniazid. Eighty-four patients (92.3%) also received DMARDs; five (5.5%) patients without DMARDs were treated with prednisolone plus TNF inhibitors and two (2.2%) patients received TNF inhibitors alone. Sixty-two patients (68.1%) at T1 and 61 (67.0%) patients at T2 were using prednisolone. The median dose of prednisolone was 5 mg/day (range: 0-10 mg/day) at T1 and 3 mg/day (range: 0-25 mg/ day) at T2, showing a significant decrease between T1 and T2 (P = 0.004).
TST reaction
The reactions to the TST at T1 and T2 are listed in Table 2 . At T1, 45 patients (49.4%) were negative, 21 (23.1%) were weakly positive, 18 (19.8%) were moderately positive and seven (7.7%) were strongly positive. At T2, 44 patients (48.3%) were negative, 20 (22.0%) were weakly positive, 16 (17.6%) were moderately positive and 11 (12.1%) were strongly positive. There were no significant differences of the TST reaction between T1 and T2 (P = 0.657).
The TST reaction was in the same range at T1 and T2 in 50 patients (54.9%), while the reaction became stronger at T2 than T1 in 21 patients (23.1%) and became weaker at T2 than T1 in 20 patients (22.0%). There was a significant correlation of the strength of the TST reaction between T1 and T2 (r = 0.491, P < 0.001). While one of seven patients who had a strongly positive TST reaction at T1 became weakly positive at T2, none of them became negative at T2. This patient in whom the reaction changed from strongly positive to weakly positive and 14 patients in whom it changed from moderately or weakly positive to negative had no signs of immunodeficiency. Two of the 45 patients with a negative TST reaction at T1 became strongly positive at T2. In both patients, RA was in clinical remission and there were no signs of TB.
We also analyzed TST data separately for patients treated with infliximab or etanercept. In patients treated with infliximab, there were no significant differences of the TST reaction between T1 and T2 (P = 0.462), and a significant correlation of the reaction was noted between T1 and T2 (r = 0.531, P < 0.001). Similarly, patients treated with etanercept showed no significant differences of the TST reaction between T1 and T2 (P = 1.00) and there was a significant correlation of the reaction between T1 and T2 (r = 0.467, P < 0.001) (data not shown).
DISCUSSION
We conducted this study to clarify whether long-term therapy with TNF inhibitors suppresses the TST reaction and whether the TST reaction increases due to the activation of LTBI. Our findings suggested that TNF inhibitors did not affect the TST reaction in Japanese RA patients.
It is well known that TNF inhibitors increase the risk of reactivation of M. tuberculosis infection in RA patients who have LTBI. Susceptibility to M. tuberculosis is explained by inhibition of cell-mediated immunity as a result of targeting TNF, which may play a pivotal role in protection against TB by promoting granulomatous inflammation and bactericidal activity. 17 The TST is a delayed-type hypersensitivity reaction (DTH) in which TNF plays a central role, suggesting the possibility that use of TNF inhibitors could suppress this reaction in RA patients. However, M. tuberculosis-specific T cells are activated by the antigens in PPD and various cytokines are involved in the TST, including TNF, interferon-c and interleukin-2. 18, 19 Previous studies have shown that accumulation of cells expressing these cytokines differs according to the DTH reaction, with interferon-c and interleukin-2 being more important for DTH to the TST. 18, 19 In the present study, the TST reaction increased in 23.1% of the patients, and two patients who were negative at T1 became strongly positive at T2. We speculate that these two patients were freshly infected with M. tuberculosis. Although no signs of TB were observed, *Significant difference between the doses of prednisolone before and during TNFi therapy (P = 0.004). †Leflunomide was started after TNFi therapy in one of these two patients. TNFi, tumor necrosis factor inhibitor; TST, tuberculin skin test; DMARDs, disease-modifying anti-rheumatic drugs.
prophylaxis with isoniazid was administered to these two patients, and no symptoms of TB have developed since then. In contrast, the TST reaction decreased in 22.0% of the patients, and none of the patients who were strongly positive at T1 became negative at T2.
Although an immunosuppressive effect of TNF inhibitors was observed in some patients, a similar number of patients showed an increase in the TST reaction. As shown in Table 2 , there were no significant differences in the TST reaction between T1 and T2 (P = 0.657), and there was a significant correlation regarding the strength of the TST reaction between T1 and T2 (r = 0.491, P < 0.001). We speculate that a change in the TST reaction during TNF inhibitor treatment may reflect differences in immune responses among individuals rather than being due to the TNF inhibitor treatment itself. Our results are in agreement with those reported from Spain, Turkey and Austria, 10, [12] [13] [14] although there are some methodological differences. BCG vaccination is routinely performed in Turkey, as in Japan. The TST reaction is judged on the basis of induration in other countries, while it is judged from both erythema and induration in Japan. The extent of erythema and induration is correlated in patients with TB. 20 There might have been a stronger booster effect on the TST reaction in the Turkish study since the interval between the first and second TST was only 4.8 months in that study compared to over 1 year in our study.
The finding that TNF inhibitors only show a small suppressive effect on the TST reaction may be useful in screening for reactivation of TB during treatment of RA with TNF inhibitors. It was reported that the TST reaction became positive from negative when a patient developed TB during treatment with a TNF inhibitor. 21 It was also reported that the IGRA became positive, while the TST reaction remained negative in some patients who developed TB during treatment with TNF inhibitors. 22 Thus, IGRA might be more sensitive for diagnosis of TB.
The influence of prednisolone and the booster effect on the results of the TST also need to be addressed. The median dose of prednisolone decreased significantly from T1 to T2 in this study. According to the American Thoracic Society, 23 the criteria for assessing the TST should be modified when a patient is treated with prednisolone at ≥ 15 mg/day because of suppression of the TST reaction. In our study, two patients were receiving prednisolone at ≥ 15 mg/day at T2 and the TST reaction became negative from weakly positive in both of them, suggesting possible immunosuppression by prednisolone. However, most of the patients were being treated with < 15 mg/day of prednisolone at T2, therefore, there was little, if any, influence on the TST reaction at the dosages used in our patients. Although a booster effect might persist at more than 1 year after initial injection of PPD, it is usually negligible after 90 days. 24 In the present study, the median interval between T1 and T2 was 2.4 years (range: 1.0-4.6 years), therefore, little booster effects would be expected. 25 In conclusion, TNF inhibitors did not suppress the TST reaction in the present study and none of our patients developed TB with an appropriate prophylaxis.
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